Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 10/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CCKBR | P32239 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | TACR2 | P21452 | 1/20 | 0.42 |
| ▸ | UGCG | Q16739 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9984002 | 1.00 | S1PR1 (0.58) | S1PR1KMT2AMEN1HPGDCCKBR | |
| SCHEMBL27840861 | 0.90 | S1PR1 (0.58) | S1PR1KMT2AMEN1HPGDCCKBR | |
| SCHEMBL1373220 | 0.90 | S1PR1 (0.58) | S1PR1KMT2AMEN1HPGDCCKBR | |
| SCHEMBL1375658 | 0.90 | S1PR1 (0.53) | S1PR1KMT2AMEN1HPGDCCKBR | |
| SCHEMBL1375660 | 0.90 | S1PR1 (0.53) | S1PR1KMT2AMEN1HPGDCCKBR | |
| SCHEMBL1375663 | 0.90 | S1PR1 (0.53) | S1PR1KMT2AMEN1HPGDCCKBR | |
| SCHEMBL1372968 | 0.90 | S1PR1 (0.57) | S1PR1KMT2AMEN1HPGDCCKBR | |
| SCHEMBL1372404 | 0.86 | S1PR1 (0.64) | S1PR1KMT2AMEN1HPGDTHRB | |
| SCHEMBL1372408 | 0.86 | S1PR1 (0.64) | S1PR1KMT2AMEN1HPGDTHRB | |
| SCHEMBL1375566 | 0.85 | S1PR1 (0.54) | S1PR1KMT2AMEN1HPGDCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802692-B2 | Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents | EXELIXIS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20110301188-A1 | Synergistic Effects Between Sphingosine-1-Phosphate Receptor Antagonists and Antimicrotubule Agents | EXELIXIS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301188-A1 | Synergistic Effects Between Sphingosine-1-Phosphate Receptor Antagonists and Antimicrotubule Agents | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885KMT2A 4096/4885MEN1 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.